Curanex Pharmaceuticals ratios data for the quarter ended Jun 2026. These financial ratios cover 4 quarters of results from Jun 2025 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|
| Efficiency | ||||
| Assets AverageAssets Avg. | 0.65M | 7.63M | 13.03M | 8.33M |
| Invested CapitalInvested Cap. | 0.71M | |||
| Leverage & Solvency | ||||
| Interest Coverage RatioInterest Cover | -18.65 | -232.60 | ||
| Debt Ratio | 0.51 | |||
| Times Interest Earned | -18.65 | -232.60 | ||
| Valuation | ||||
| Price to EarningsP/E | -1.07 | -0.15 | -0.12 | |
| Price to BookP/B | 0.07 | 0.04 | 0.08 | |
| Enterprise Value | -4.81M | -4.50M | -2.56M | |
| EV to EBIT | 5.06 | 1.46 | 0.77 | |
| EV to EBITDA | 5.06 | 1.46 | 0.77 | |
| Market Capitalization | 1.02M | 0.47M | 0.38M | |
| Price to FCFP/FCF | -0.11 | -0.55 | ||
| EV to FCF | 0.52 | 5.25 | ||
| EV to CFO | 0.52 | 5.25 | ||
| Return Ratios | ||||
| Return on Capital Employed [ROCE]ROCE | -16.78% | -32.96% | -90.33% | |
| Return on Assets [ROA]ROA | -16.47% | -32.67% | -89.28% |